X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ajovy is a FDA approved, humanized monoclonal antibody (mAb) which selectively binds the calcitonin gene-related peptide (CGRP). It is being investigated for the prevention of migraine in adult Chinese patients.
Lead Product(s): Fremanezumab
Therapeutic Area: Neurology Product Name: Ajovy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
mAbxience will leverage its expertise in biosimilar development to develop and produce the biosimilar product currently in development for the treatment of multiple oncology indications.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: Mabxience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 04, 2024
Details:
The collaboration aims to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-56248), albuterol/fluticasone combination, currently in Phase 3 clinical trials for patients with asthma.
Lead Product(s): Fluticasone Propionate,Salbutamol Sulphate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TEV-56248
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Launch Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 01, 2024
Details:
The net proceeds will be used to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-56248), albuterol/fluticasone combination, currently in Phase 3 clinical trials for patients with asthma.
Lead Product(s): Fluticasone Propionate,Salbutamol Sulphate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TEV-56248
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Abingworth
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 01, 2024
Details:
Under the agreement, Teva will use Closed Loop Medicine’s proprietary SaMD platform which advances the development of personalised medicines, including CLM-HT01 (amlodipine), in patients with chronic disorders by combining dose-optimised drug therapy with digital care.
Lead Product(s): Amlodipine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CLM-HT01
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Closed Loop Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 26, 2024
Details:
The partnership aims to focus on the commercialization of Teva’s Austedo (deutetrabenazine). It is approved by the U.S. FDA in adults for the treatment of tardive dyskinesia and for the chorea associated with Huntington’s disease.
Lead Product(s): Deutetrabenazine
Therapeutic Area: Genetic Disease Product Name: Austedo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Jiangsu Nhwa Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 26, 2024
Details:
Simlandi (adalimumab) is the first interchangeable, high-concentration, citrate-free biosimilar to Humira approved for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis and Crohn’s disease.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Simlandi
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Alvotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
TEV-44749 (olanzapine) is a novel D2/5-HT2 receptor inhibitor which is under phase 3 clinical development for the treatment of patients with Schizophrenia.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Product Name: TEV-44749
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: MedinCell
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
Under the acquisition, Essential Pharma has acquired the rights to Colobreathe (colistimethate sodium), indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa (PsA) in patients with cystic fibrosis, across European markets.
Lead Product(s): Colistimethate Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Colobreathe
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Essential Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 08, 2024
Details:
Under the agreement, Teva will receive exclusive rights to develop, manufacture and commercialize a potential novel antibody-based therapy, BD9, a dual specific antibody that can block both TSLP and IL-13, for the treatment of Atopic Dermatitis and Asthma.
Lead Product(s): BD9
Therapeutic Area: Dermatology Product Name: BD9
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Biolojic Design
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
